Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 3, 2024
Abstract
The
development
of
cancer
vaccines
is
at
the
forefront
immunotherapy.
Most
existing
strategies
to
induce
an
efficient
anti‐tumor
immune
response
rely
on
molecular
adjuvants
and
incorporation
complex
synthetic
vectors
into
vaccine
formulations.
In
contrast,
this
study
introduces
a
one‐step
engineering
technique
assemble
model
antigen,
Ovalbumin
(OVA),
amyloid
aggregates,
leveraging
biomimetic
folding
aggregation
create
non‐fibrillar
OVA
globular
aggregates
amyloid‐like
fibrils
as
single‐component,
adjuvant‐free
vaccines.
Notably,
induced
stronger
responses
compared
native
form,
evidenced
by
robust
humoral
reactions
establishment
memory.
These
enhanced
can
be
attributed
self‐adjuvant
effect
unique
assembled
structure,
which
preserves
antigenic
epitopes,
improves
antigen
stability,
facilitates
internalization,
prolongs
retention
injection
site,
enhances
trafficking
lymphoid
organs,
promotes
increased
secretion
antibodies
cytokines.
Furthermore,
efficacy
was
validated
in
high
OVA‐expressing
tumor
model,
demonstrating
potential
effective
for
immunoprevention.
This
minimalist
strategy
holds
promising
implications
immunotherapy
inform
design
other
protein
antigen‐based
Molecular Cancer,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: Feb. 24, 2025
As
one
part
of
the
innate
immune
response
to
external
stimuli,
chronic
inflammation
increases
risk
various
cancers,
and
tumor-promoting
is
considered
enabling
characteristics
cancer
development.
Recently,
there
has
been
growing
evidence
on
role
anti-inflammation
therapy
in
prevention
treatment.
And
researchers
have
already
achieved
several
noteworthy
outcomes.
In
review,
we
explored
underlying
mechanisms
by
which
affects
occurrence
development
cancer.
The
pro-
or
anti-tumor
effects
these
inflammatory
factors
such
as
interleukin,
interferon,
chemokine,
inflammasome,
extracellular
matrix
are
discussed.
Since
FDA-approved
drugs
like
aspirin
show
obvious
effects,
unique
advantages
due
their
relatively
fewer
side
with
long-term
use
compared
chemotherapy
drugs.
make
them
promising
candidates
for
chemoprevention.
Overall,
this
review
discusses
molecules
carcinogenesis
new
molecules-directed
therapeutic
opportunities,
ranging
from
cytokine
inhibitors/agonists,
inflammasome
inhibitors,
some
inhibitors
that
expected
be
applied
clinical
practice,
well
recent
discoveries
effect
non-steroidal
anti-inflammatory
steroidal
disadvantages
application
chemoprevention
also
Science Immunology,
Journal Year:
2025,
Volume and Issue:
10(103)
Published: Jan. 17, 2025
Immune
responses
against
cancer
are
dominated
by
T
cell
exhaustion
and
dysfunction.
Recent
advances
have
underscored
the
critical
role
of
early
priming
interactions
in
establishing
fates.
In
this
review,
we
explore
importance
dendritic
(DC)
signals
specifying
CD8+
fates
cancer,
drawing
on
insights
from
acute
chronic
viral
infection
models.
We
highlight
DCs
lymph
nodes
tumors
maintaining
stem-like
cells,
which
for
durable
antitumor
immune
responses.
Understanding
how
determined
will
enable
rational
design
immunotherapies,
particularly
therapeutic
vaccines,
that
can
modulate
DC-T
to
generate
beneficial
Journal of Clinical Investigation,
Journal Year:
2025,
Volume and Issue:
135(1)
Published: Jan. 1, 2025
Cutaneous
squamous
cell
carcinoma
(cSCC)
incidence
and
deaths
continue
to
rise,
underscoring
the
need
for
improved
cSCC
prevention.
Elimination
of
actinic
keratosis
(AK)
precursor
lesions
is
a
major
strategy
prevent
cSCC.
Topical
calcipotriol
5-fluorouracil
(5-FU)
have
been
shown
eliminate
AKs
reduce
risk
development,
but
mechanism
was
undefined.
In
this
issue
JCI,
Oka
et
al.
demonstrate
that
type
2
immunity
necessary
sufficient
elimination
premalignant
keratinocytes
Paired
biopsies
from
AK
unaffected
skin
revealed
only
produced
thymic
stromal
lymphopoietin
(TSLP)
damage-associated
molecular
patterns,
resulting
in
selective
recruitment
Th2
cells
lesion.
mouse
models
carcinogenesis,
TSLP
recruit
trigger
IL-24-mediated
keratinocyte
death.
These
findings
suggest
TSLP/Th2/IL-24
axis
potential
therapeutic
target
SCC
Immunometabolism,
Journal Year:
2025,
Volume and Issue:
7(1), P. e00055 - e00055
Published: Jan. 1, 2025
The
approval
of
chimeric
antigen
receptor
(CAR)
T
cell
therapies
for
the
treatment
hematological
cancers
has
marked
a
new
era
in
cancer
care,
with
seven
products
being
FDA
approved
since
2017.
However,
challenges
remain,
and
while
profound
effects
are
observed
initially
myeloma,
majority
patients
relapse,
which
is
concomitant
poor
CAR
persistence.
Similarly,
efficacy
therapy
limited
solid
tumors,
largely
due
to
tumor
heterogeneity,
immune
evasion
mechanisms,
infiltration
In
this
recent
study,
Guerrero
et
al
endeavor
improve
human
cells
by
overexpressing
glucose
transporter
GLUT1
show
that
have
improved
capacity
persist
control
burden
vivo.
Over
the
recent
decades
market
potential
of
biologics
has
substantially
expanded,
and
many
top-selling
drugs
worldwide
are
now
monoclonal
antibodies
or
antibody-like
molecules.
The
common
gamma
chain
(γc)
cytokines,
Interleukin
(IL-)2,
IL-4,
IL-7,
IL-9,
IL-15,
IL-21,
play
pivotal
roles
in
regulating
immune
responses,
from
innate
to
adaptive
immunity.
Dysregulation
cell
signaling
by
these
cytokines
is
strongly
associated
with
a
range
immunological
disorders,
which
includes
cancer
as
well
autoimmune
inflammatory
diseases.
Given
essential
role
γc
maintaining
homeostasis,
development
therapeutic
interventions
targeting
molecules
poses
unique
challenges.
Here,
we
provide
an
overview
current
either
single
multiple
their
respective
receptor
subunits
across
spectrum
diseases,
primarily
focusing
on
antibodies,
constructs,
antibody-cytokine
fusions.
We
summarize
currently
clinical
trials,
highlighting
how
they
may
offer
advantages
over
existing
therapies
standard
care,
discuss
advances
this
field.
Finally,
explore
future
directions
novel
intervention
strategies
cytokine
family.
